* a confirmed case of novel coronavirus infection or asymptomatic infection or a history of positive novel coronavirus nucleic acid test; * patients with uncontrolled lymphoproliferative diseases, unresolved aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled coagulopathy, etc; * patients with malignant tumors before and after surgery, patients undergoing chemotherapy, radiotherapy, immunotherapy, etc.; patients with organ transplantation status; * people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.); * suffering from acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases, such as hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmhg and/or diastolic blood pressure ≥100mmhg); * previous history of severe allergies to any vaccine, or history of severe allergies to any component of the test vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, vascular nerve sexual edema, etc; * women who are breastfeeding or pregnant; * in addition to completing the recombinant novel coronavirus vaccine (cho cell) within the past 7 months, has participated or is participating in other covid-19 related clinical trials; * investigators believe that any disease or condition may put the subject at an unacceptable risk; the subject cannot meet the requirements of the protocol; the situation that interferes with the assessment of the vaccine response.

* a confirmed case of novel coronavirus infection or asymptomatic infection or a history of positive novel coronavirus nucleic acid test; * patients with uncontrolled lymphoproliferative diseases, unresolved aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled coagulopathy, etc; * patients with malignant tumors before and after surgery, patients undergoing chemotherapy, radiotherapy, immunotherapy, etc.; patients with organ transplantation status; * people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.); * suffering from acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases, such as hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmhg and/or diastolic blood pressure ≥100mmhg); * previous history of severe allergies to any vaccine, or history of severe allergies to any component of the test vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, vascular nerve sexual edema, etc; * women who are breastfeeding or pregnant; * in addition to completing the recombinant novel coronavirus vaccine (cho cell) within the past 7 months, has participated or is participating in other covid-19 related clinical trials; * investigators believe that any disease or condition may put the subject at an unacceptable risk; the subject cannot meet the requirements of the protocol; the situation that interferes with the assessment of the vaccine response.

a confirmed case of novel coronavirus infection or asymptomatic infection or a history of positive novel coronavirus nucleic acid test; patients with uncontrolled lymphoproliferative diseases, unresolved aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled coagulopathy, etc; patients with malignant tumors before and after surgery, patients undergoing chemotherapy, radiotherapy, immunotherapy, etc.; patients with organ transplantation status; people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.); suffering from acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases, such as hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmhg and/or diastolic blood pressure ≥100mmhg); previous history of severe allergies to any vaccine, or history of severe allergies to any component of the test vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, vascular nerve sexual edema, etc; women who are breastfeeding or pregnant; in addition to completing the recombinant novel coronavirus vaccine (cho cell) within the past 7 months, has participated or is participating in other covid-19 related clinical trials; investigators believe that any disease or condition may put the subject at an unacceptable risk; the subject cannot meet the requirements of the protocol; the situation that interferes with the assessment of the vaccine response.

a confirmed case of novel coronavirus infection or asymptomatic infection or a history of positive novel coronavirus nucleic acid test; patients with uncontrolled lymphoproliferative diseases, unresolved aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled coagulopathy, etc; patients with malignant tumors before and after surgery, patients undergoing chemotherapy, radiotherapy, immunotherapy, etc.; patients with organ transplantation status; people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain-barre syndrome, demyelinating diseases, etc.); suffering from acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases, such as hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmhg and/or diastolic blood pressure ≥100mmhg); previous history of severe allergies to any vaccine, or history of severe allergies to any component of the test vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, dyspnea, vascular nerve sexual edema, etc; women who are breastfeeding or pregnant; in addition to completing the recombinant novel coronavirus vaccine (cho cell) within the past 7 months, has participated or is participating in other covid-19 related clinical trials; investigators believe that any disease or condition may put the subject at an unacceptable risk; the subject cannot meet the requirements of the protocol; the situation that interferes with the assessment of the vaccine response.